Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors
Myeloid cells constitute a significant part of the immune system in the context of cancer, exhibiting both immunostimulatory effects, through their role as antigen presenting cells, and immunosuppressive effects, through their polarization to myeloid-derived suppressor cells (MDSCs) and tumor-associ...
Main Authors: | Andy S. Ding, Denis Routkevitch, Christina Jackson, Michael Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01715/full |
Similar Items
-
Advances in Anti-tumor Therapy of Myeloid-derived Suppressor Cells Combined with Immunological Checkpoint Inhibitors
by: SUN Haiyan, et al.
Published: (2020-09-01) -
Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy
by: Houhui Shi, et al.
Published: (2021-07-01) -
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
by: Rebekka Weber, et al.
Published: (2018-06-01) -
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
by: Andrew M. K. Law, et al.
Published: (2020-02-01) -
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
by: Franziska K. Krebs, et al.
Published: (2021-03-01)